About The Study: In this cohort study, receipt of the 2024-2025 COVID-19 vaccine was associated with reduced risk of COVID-19–associated major adverse cardiovascular event (MACE), with reductions most prominent in those 75 years or older and those with comorbidities. While the reduction in COVID-19–associated MACE was modest, the substantially larger reduction in all-cause MACE suggests that the vaccine’s protective association extends to the hidden burden of undetected SARS-CoV-2 and its sequelae.
Corresponding Author: To contact the corresponding author, Ziyad Al-Aly, MD, email ziyad.alaly@va.gov.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamainternmed.2026.1929)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2026.1929?guestAccessKey=d13423b6-0f97-447a-a381-df38354146d7&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061526
Journal
JAMA Internal Medicine